FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib

[1]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[2]  R. Clark,et al.  The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia , 2003, British journal of haematology.

[3]  K. Krohn,et al.  Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. , 2003, Blood.

[4]  H. Kantarjian,et al.  Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  R. Clark,et al.  Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia , 2002, British journal of haematology.

[6]  R. Silver,et al.  Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. , 2002, Cancer genetics and cytogenetics.

[7]  P. Paschka,et al.  Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α , 2002, Leukemia.

[8]  J. Issa,et al.  Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[10]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[11]  W. Hiddemann,et al.  Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases , 2002, Leukemia.

[12]  D. Marin,et al.  The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. , 2002, Haematologica.

[13]  I. Kottke,et al.  Predominantly BCR-ABL negative myeloid precursors in interferon-α treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization , 2001, Annals of Hematology.

[14]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[15]  M. Deininger,et al.  No evidence for persistence of BCR-ABL–positive cells in patients in molecular remission after conventional allogeneic transplantation for chronic myeloid leukemia , 2000 .

[16]  R. Bataille,et al.  Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Kantarjian,et al.  New treatment approaches for chronic myelogenous leukemia. , 2000, Seminars in Oncology.

[18]  D. Niederwieser,et al.  No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogenic transplantation for chronic myeloid leukemia. , 2000, Blood.

[19]  H. Kantarjian,et al.  Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  T. Naoe,et al.  Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells , 1999, Leukemia.

[21]  N. Takahashi,et al.  Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. , 1998, Blood.

[22]  P. Thall,et al.  Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  G. Utermann,et al.  Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome‐positive chronic myeloid leukemia (CML) during interferon treatment: A new strategy for remission assessment , 1998, Genes, chromosomes & cancer.

[24]  M. Miller,et al.  Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders. , 1998, American journal of clinical pathology.

[25]  I. Leukemia.  Long term follow up of the italian trial of Interferon-A versus conventional chemotherapy in Chronic Myeloid Leukemia , 1998 .

[26]  D. Niederwieser,et al.  Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the philadelphia translocation and can induce a CML‐specific primary cytotoxic T‐cell response , 1997, Genes, chromosomes & cancer.

[27]  A. Green,et al.  Improved sensitivity of BCR-ABL detection: a triple-probe three-color fluorescence in situ hybridization system. , 1997, Blood.

[28]  M. Tribalto,et al.  FISH analysis for CML monitoring ? , 1996, Annals of Hematology.

[29]  A. Ganser,et al.  Fluorescence in situ hybridization (FISH) is a reliable diagnostic tool for detection of the 9;22 translocation. , 1996, Leukemia & lymphoma.

[30]  N. Schmitz,et al.  Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group. , 1996, Bone marrow transplantation.

[31]  J. Goldman,et al.  Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. , 1996, Blood.

[32]  M. Tribalto,et al.  Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy , 1995 .

[33]  M. Tribalto,et al.  Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy. , 1995, Cancer genetics and cytogenetics.

[34]  H. Heimpel,et al.  Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. , 1994, Blood.

[35]  A. Chase,et al.  T lymphocytes in chronic myelogenous leukaemia (CML): no evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridization in 14 patients. , 1994, Leukemia.

[36]  A. Chase,et al.  Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. , 1993, Blood.

[37]  R. Kurzrock,et al.  Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. , 1991, Annals of internal medicine.

[38]  R. Gale,et al.  Chronic myeloid leukemia. , 1992, The American journal of medicine.